Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 1450 of 3499 entries
View as:

Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement

Phase: N/A Priority: Normal
NCT ID: NCT03701295 Org: User:
Start: 03/06/20 End: 01/12/21 Due: 01/12/22

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Phase: N/A Priority: Normal
NCT ID: NCT05554393 Org: User:
Start: 09/13/24 End: 12/31/25 Due: 12/31/26

Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT01130506 Org: User:
Start: 05/17/10 End: - Due: -

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

Phase: N/A Priority: Normal
NCT ID: NCT05773274 Org: User:
Start: 01/12/24 End: 04/30/26 Due: 04/30/27

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05237986 Org: User:
Start: 06/23/25 End: 04/30/27 Due: 04/30/28

Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma

Phase: N/A Priority: Normal
NCT ID: NCT00650923 Org: User:
Start: 07/31/08 End: 12/31/13 Due: 12/31/14

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

Phase: N/A Priority: Normal
NCT ID: NCT00242723 Org: User:
Start: 11/09/05 End: - Due: -

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

Phase: N/A Priority: Normal
NCT ID: NCT04439344 Org: User:
Start: 05/31/16 End: 03/19/26 Due: 03/19/27

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT03036930 Org: User:
Start: 06/23/17 End: 03/06/26 Due: 03/06/27

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT03798678 Org: User:
Start: 07/08/19 End: 01/30/26 Due: 01/30/27

Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00377104 Org: User:
Start: 09/30/06 End: - Due: -

O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00003613 Org: User:
Start: 04/30/99 End: - Due: -

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02314169 Org: User:
Start: 05/13/15 End: 03/21/26 Due: 03/21/27

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Phase: N/A Priority: Normal
NCT ID: NCT04514484 Org: User:
Start: 11/22/21 End: 11/02/25 Due: 11/02/26

Edrecolomab in Treating Patients With Stage II Colon Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00002968 Org: User:
Start: 05/31/97 End: - Due: -

Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00331955 Org: User:
Start: 03/31/06 End: - Due: -

EF5 in Treating Patients With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00003282 Org: User:
Start: 03/31/98 End: - Due: -

Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05985681 Org: User:
Start: 02/27/25 End: 06/01/27 Due: 06/01/28

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

Phase: N/A Priority: Normal
NCT ID: NCT00033371 Org: User:
Start: 12/13/01 End: 03/24/09 Due: 03/24/10

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00019214 Org: User:
Start: 04/30/97 End: 07/31/06 Due: 07/31/07

p53 Vaccine for Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00001827 Org: User:
Start: 07/26/99 End: 01/25/13 Due: 01/25/14

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT03038672 Org: User:
Start: 12/21/18 End: 10/25/25 Due: 10/25/26

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT02152982 Org: User:
Start: 12/15/14 End: 12/26/25 Due: 12/26/26

Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00112684 Org: User:
Start: 02/28/06 End: - Due: -

Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01789255 Org: User:
Start: 06/30/13 End: 03/31/14 Due: 03/31/15